INO-4800 DNA疫苗可诱导针对全球新冠病毒变异株的中和抗体和T细胞活性。
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants.
作者信息
Andrade Viviane M, Christensen-Quick Aaron, Agnes Joseph, Tur Jared, Reed Charles, Kalia Richa, Marrero Idania, Elwood Dustin, Schultheis Katherine, Purwar Mansi, Reuschel Emma, McMullan Trevor, Pezzoli Patrick, Kraynyak Kim, Sylvester Albert, Mammen Mammen P, Tebas Pablo, Joseph Kim J, Weiner David B, Smith Trevor R F, Ramos Stephanie J, Humeau Laurent M, Boyer Jean D, Broderick Kate E
机构信息
Inovio Pharmaceuticals, Plymouth Meeting, PA, USA.
Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, PA, USA.
出版信息
NPJ Vaccines. 2021 Oct 14;6(1):121. doi: 10.1038/s41541-021-00384-7.
Global surveillance has identified emerging SARS-CoV-2 variants of concern (VOC) associated with broadened host specificity, pathogenicity, and immune evasion to vaccine-induced immunity. Here we compared humoral and cellular responses against SARS-CoV-2 VOC in subjects immunized with the DNA vaccine, INO-4800. INO-4800 vaccination induced neutralizing antibodies against all variants tested, with reduced levels detected against B.1.351. IFNγ T cell responses were fully maintained against all variants tested.
全球监测已发现新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株（VOC），这些变异株具有更广泛的宿主特异性、致病性，并能逃避免疫接种诱导的免疫。在此，我们比较了接种DNA疫苗INO-4800的受试者针对SARS-CoV-2变异株的体液免疫和细胞免疫反应。接种INO-4800疫苗可诱导针对所有测试变异株的中和抗体，但针对B.1.351变异株的中和抗体水平有所降低。针对所有测试变异株，γ干扰素T细胞反应均完全得以维持。
Zotero 插件